Diabetes and Dementia: A Metabolic Link Every Hospice and Palliative Care Provider Must Understand

As the population ages and chronic disease burdens deepen, palliative care and hospice teams are increasingly faced with the intersecting trajectories of metabolic and neurodegenerative disease. Among the most clinically significant—and often overlooked—intersections is the strong association between Type 2 diabetes and Alzheimer's disease. Understanding this link isn't just an academic exercise. It may reshape how we identify risk, manage symptoms, and communicate prognosis for patients facing cognitive decline.

Type 3 Diabetes: A Concept with Clinical Relevance

The term “Type 3 diabetes” has emerged in the literature to describe insulin resistance within the brain—specifically as it pertains to Alzheimer’s disease. While not an official diagnostic category, the term captures a growing body of research linking metabolic dysfunction to neurodegeneration.

In Alzheimer’s disease, neurons in the hippocampus and cortex begin to show impaired insulin signaling, much like peripheral cells do in Type 2 diabetes. This neuronal insulin resistance contributes to impaired glucose utilization, increased oxidative stress, and eventually neuronal death—all preceding the onset of noticeable memory loss. Some imaging studies reveal glucose hypometabolism in the brains of Alzheimer’s patients up to 10 years before clinical symptoms emerge.

For palliative care providers, this has profound implications: many of our patients with dementia may also carry a legacy of long-standing metabolic disease.

The Overlapping Pathophysiology of Diabetes and Alzheimer’s

What makes this connection so important for clinical care?

• Insulin Resistance: Both Type 2 diabetes and Alzheimer’s involve tissue resistance to insulin. In the brain, this affects synaptic plasticity, memory consolidation, and neurotransmitter regulation.
• Amyloid Pathology: High insulin levels may impair clearance of beta-amyloid, the hallmark protein that accumulates in Alzheimer’s. This is because insulin-degrading enzyme (IDE) also breaks down amyloid; if it's busy processing chronically elevated insulin, amyloid clearance suffers.
• Inflammation and Oxidative Stress: Both conditions promote chronic low-grade inflammation and mitochondrial dysfunction, accelerating cellular aging and injury.
• Vascular Contribution: Diabetes accelerates microvascular damage, which further impairs cerebral perfusion, especially in white matter tracts critical to executive function and memory.

Clinical Implications for Hospice Eligibility and Symptom Management

1. Earlier Cognitive Decline in Diabetics

Studies have shown that individuals with Type 2 diabetes have a 59% higher risk of developing dementia. This risk rises with longer disease duration and poor glycemic control. In the hospice setting, a patient with both advanced diabetes and dementia may meet criteria for admission sooner due to compounded functional decline.

2. Cachexia and Sarcopenia

Chronic insulin resistance impairs muscle protein synthesis and promotes catabolic cytokine activity. This contributes to early sarcopenia and cachexia, often seen in patients with diabetes and dementia who begin to lose weight, appetite, and mobility—key indicators for hospice eligibility.

3. Communication and Prognostication

Understanding the diabetes-dementia link allows us to have more informed conversations with families about the synergistic decline their loved ones are experiencing. It’s not simply “old age” or “bad luck”—it’s the downstream impact of decades of metabolic dysfunction.

What This Means for Your Interdisciplinary Team

• Physicians: When evaluating patients for hospice eligibility under Alzheimer’s or related dementia LCDs, document underlying metabolic drivers like long-standing Type 2 diabetes, weight loss, and decreased oral intake as accelerating factors.
• Nurses: Monitor for signs of hypoglycemia and consider deprescribing insulin or sulfonylureas in end-of-life care. Tight glycemic control is no longer the goal.
• Social Workers and Chaplains: Families may struggle with guilt about their loved one’s condition. Reframing Alzheimer’s as a metabolic disease may help families understand this isn’t a personal failing—it’s a systemic process that began decades earlier.
• Dietitians: Educate families on appropriate nutrition goals for advanced dementia patients with diabetes—low carb isn't the priority anymore. Preventing hypoglycemia and supporting comfort are paramount.

Preventive Perspective: Beyond the Bedside

For providers involved in upstream palliative care or serious illness conversations in middle age, this information is critical. Educating patients in their 40s and 50s that hemoglobin A1c isn't just about heart disease—it’s about brain health—can change lives. Type 2 diabetes and its precursor, insulin resistance, are modifiable risk factors. Unlike genetic mutations such as APOE4, metabolic risk can be prevented, delayed, or even reversed.

Emerging Treatments and Research

• Metformin: Several studies suggest it may reduce dementia risk in diabetics, possibly due to its insulin-sensitizing and anti-inflammatory effects.
• GLP-1 Agonists (Ozempic, Wegovy): Preliminary research shows neuroprotective effects, leading to new trials investigating their role in delaying cognitive decline.
• Ketogenic Diets and Time-Restricted Eating: Though not practical in advanced disease, these strategies may be worth exploring in early cognitive decline under medical supervision.

Final Thoughts: Bridging the Gap in Hospice Care

Too often, providers compartmentalize chronic illnesses: diabetes over here, dementia over there. But for the patient lying in a hospice bed, these are not separate issues. They are the same story, written in different chapters. If we don’t connect the dots, we miss the full picture of suffering—and of opportunity.

As palliative and hospice providers, we must recognize that Alzheimer’s isn’t just a disease of forgetting. It’s often the final chapter of decades-long metabolic dysfunction. And while we cannot change the past for our current patients, we can advocate for future generations to approach dementia with the same energy we give to heart disease, stroke, and cancer.

Because the brain, too, is an organ vulnerable to the effects of insulin.

References:

1. Suzanne M. de la Monte. Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review. European Neuropsychopharmacology. Volume 24, Issue 12, 2014, Pages 1954-1960.
2. Arnold, S.E., et al. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nature Reviews Neurology, 14, 168–181.
3. Biessels, G.J., Strachan, M.W.J., Visseren, F.L.J., Kappelle, L.J., Whitmer, R.A. (2014). Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. The Lancet Diabetes & Endocrinology, 2(3), 246–255.
4. Chatterjee, S., Peters, S.A., Woodward, M., et al. (2016). Type 2 diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care, 39(2), 300–307.
5. Craft, S. (2009). The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Archives of Neurology, 66(3), 300–305.